This is evident in bevacizumab’s capacity to induce direct cytotoxic effects in various tumor cells expressing high VEGFA levels (Miranda-Goncalves et al., 2017; Zhao et al., 2018; Suo et al., 2020; Alonso-Diez et al., 2021; Fan et al., 2022; Wei et al., 2023). The gene discussed is VEGFA; the disease is neoplasm.